UB Researcher To Conduct First Study Of Possible Link Between Prostate Cancer And Estrogen Metabolism

May 04, 1998

BUFFALO, N.Y. -- The first investigation of the role of estrogen metabolism in the development of prostate cancer will begin at the University at Buffalo in October, funded by a $450,000 grant from the U.S. Army's Medical Research and Material Command.

The 30-month study will determine if differences in estrogen metabolism exist between healthy men and men who develop prostate cancer. Information on lifestyle habits also will be collected to determine if, as suspected, these habits affect whether estrogen breaks down into a potent product that may induce prostate-cell division, or a weak version that acts to discourage it.

This never-before-examined mechanism represents a potential new avenue of strategies to prevent this important disease, said Paola Muti, M.D., UB assistant professor of social and preventive medicine and lead investigator on the research. Prostate cancer is the second leading cause of cancer deaths among men.

The American Cancer Society estimates that 39,200 men will die of the disease in 1998 in the U.S.

"Estrogen metabolism has never been studied in men, especially in relation to prostate-cancer risk," Muti said. "Yet, men also produce estrogen, and we know that estrogen plays a role in the development of cancers in women. There is evidence also that androgens, the group of hormones responsible for male characteristics that are present in small amounts in women, are increased in women who develop breast cancer later in life."

Muti's goal is to determine if estrogen metabolism is influenced by environment and lifestyle in a way that increases prostate-cancer risk. The increase in prostate-cancer deaths among men who emigrate from countries with low rates to the United States, where rates are high, suggests that environmental factors play a dominate role in the disease, she said.

"There is evidence that a sedentary life style and high-fat diet influence estrogen metabolism to produce a potent estrogen, while an active life style and low-fat diet induce production of a weak estrogen. Potent estrogens may increase prostate-cell division and increase cancer risk. It's possible that the influence of these lifestyle factors on hormone metabolism, especially estrogen metabolism, could be the link between environment and prostate-cancer risk."

###




University at Buffalo

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.